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Delirium is an acute alteration in mental status that impairs cognitive and physical functions. It 
presents with inattention, hallucinations, agitation, and overall cognitive and perceptual 
disturbances. Although older populations tend to experience delirium more frequently, the 
incidence of delirium in the intensive care unit (ICU) occurs in up to 80% of the population 
regardless of age. ICU delirium not only creates acute consequences for patients, but also may 
negatively affect patient outcomes in the long-term. Studies have associated ICU delirium with 
longer hospital stay, longer period of mechanical ventilation, increased incidence of cognitive 
impairment at discharge, and increased mortality risk regardless of age, sex, race, and severity of 
illness. Nonetheless, current delirium prevention, diagnosis, and treatment are inadequate due to a 
lack of understanding of its pathology.  
This study aimed to explore a relationship between the biomarker interleukin-6 (IL-6) and 
delirium. Specifically, IL-6 has a polymorphism at position -174 of C/G that has shown to have 
effects on IL-6 production in different disease processes. This polymorphism was examined in 
relation to delirium for a relationship that may help explain delirium’s pathogenesis. The first 
specific aim was to explore if higher frequencies of a specific allele of IL-6 were present in patients 
who developed delirium. The second aim was to explore if a specific allele is also associated with 
more days of delirium. DNA was extracted from blood samples collected by a parent study and 
analyzed utilizing allelic discrimination in the Applied Biosystems ™ QuantStudio™ 3 Real-Time 
PCR System.  
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Data analysis included descriptive statistics, Pearson chi-square tests, univariate analyses, 
t-tests comparing genotype and days of delirium experienced, and a binary logistic regression 
model. These tests were utilized to find any association between IL-6 -174 genotypes (alleles C/G) 
with delirium and delirium positive days. We did not find statistically significant conclusions to 
support a specific genotype as being associated with delirium and delirium positive days. 
Additional studies that explore biomarkers in the role of delirium are needed to further investigate 
the biology and pathology of delirium to promote the development of proper prevention, diagnosis, 
and treatment in ICU patients and improve patient outcomes.  
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1.0  INTRODUCTION 
In the intensive care unit (ICU), patients’ bodies undergo extreme stress due to critical illness and 
life-saving medicine. One complication of the physical and psychologic stress, exacerbated by the 
disruptive environment, is delirium. Delirium is an acute change in mental status that impairs 
cognitive and physical function presenting as the inability to focus, visual hallucinations, and 
agitation.2 Particularly in the ICU, delirium is sometimes expressed as a decrease in level of 
consciousness and decreased interaction with the environment. Studies have found that delirium 
is associated with longer hospital stay, longer period of mechanical ventilation, higher incidence 
of cognitive impairment at discharge and up to one year later, and increased mortality regardless 
of the severity of illness, age, gender, and race. 1,2,21 Additionally, the cost of hospital stay is 
substantially greater for those who experience delirium, and potentially even 20% greater if it were 
not for the association of early ICU mortality.3 While delirium commonly presents in hospitalized 
or post-operative older adults, delirium rates are higher in ICU patients. In the ICU, the incidence 
of delirium is up to 80% of patients and inflicts people of all ages.4 
Even with these significant and poor outcomes, delirium is underdiagnosed and therefore 
inadequately managed.2 Tools such as the Confusion Assessment Method (CAM) and a specialized 
Confusion Assessment Method for Intensive Care Unit (CAM-ICU) are utilized by doctors and 
nurses at the bedside to determine the presence and monitor the severity of delirium in patients.5 
There are barriers decreasing the usability of the CAM-ICU.6 Nurses reported that the CAM-ICU 
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was more of a complicated task added to their already extensive workload, rather than a beneficial 
tool that supplements a routine physical assessment of the patient.6 Researchers noted that the 
utilization of the CAM-ICU had lower performance when completed by the bedside nurses, but 
high sensitivity and specificity when completed by research nurses.8 Another disadvantage to the 
CAM-ICU is that it requires the patient to be experiencing delirium symptoms at the time of 
assessment. The Intensive Care Delirium Screening Checklist (ICDSC) is a delirium monitoring 
tool that evaluates patient behaviors over a period of 8-24 hours for delirium symptoms: level of 
consciousness, inattention, disorientation, hallucinations/delusions/psychosis, psychomotor 
agitation or retardation, inappropriate speech or mood, sleep/wake cycle disturbances, and 
symptom fluctuation.22 An important difference between the CAM-ICU and the ICDSC exists in 
the timing of the exam. The CAM-ICU assesses and scores a patient only at the time of the exam, 
whereas the ICDSC accounts for temporal symptom fluctuation over a longer time frame when 
calculating the final score.23 Regardless of the tool used, discrepancy between assessments can 
easily occur with the lack of objective material, especially in the mechanically ventilated patient 
population. Additional limitations to these tools include potential for recall bias and knowledge 
discrepancies when implementing. While these tools are both fairly easy to use and have good 
reliability and validity, it has been proposed that delirium may be missed 36% of the time with the 
ICDSC and 38% of the time with the CAM-ICU.29 With serious implications associated with 
delirium, it is imperative to optimize assessment tools’ sensitivity to delirium detection.  
van den Boogaard et al.8 completed the first delirium prediction study in ICU patients. 
Their PREdiction of DELIRium for Intensive Care patients (PRE-DELIRIC) model includes 10 
weighted risk factors that are accessible within 24 hours after intensive care admission: age, 
APACHE-II score, admission category, coma, infection, metabolic acidosis, use of sedatives and 
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morphine, urea concentration, and urgent admission.8 The PRE-DELIRIC model had excellent 
predictive ability – a 0.87 area under the receiver operating characteristics curve with a 95% 
confidence interval 0.85 to 0.89.8 It has good validity compared to intensive care nurses’ and 
physicians’ assessments, (N=124).8 Ultimately, the PRE-DELIRIC model proved superior (0.87; 
0.81-0.93) in predicting delirium compared to the nurses (0.59, 0.49 to 0.70) and physicians (0.59, 
0.49 to 0.70).8 The model has been used in six different countries for ICU patients with similar 
results.10 This powerful tool would be able to help providers implement early intervention and 
prevent delirium in patients, which is crucial in improving patient outcomes.10 Nonetheless, the 
PRE-DELIRIC model has not been implemented worldwide, most likely due to its limitations 
including a lack of incorporation of temporal changes in physiologic state over the ICU admission.8 
In the ICU, patients can experience rapid changes in their health status in short periods of time, 
and with these changes the risk of the development of delirium will change as well. Implementation 
of the PRE-DELIRIC model into clinical care requires development of a computer program to 
query admission medical records, or dedicated staff, to identify risk with follow up communication 
to staff. Despite these tools for predicting and assessing for developing delirium, they are not 
routinely utilized in all ICU’s, meaning a considerable proportion of delirium is not identified or 
treated. A biomarker, genetic or otherwise, capable of predicting delirium risk would greatly 
enhance the ability to provide improved individualized surveillance, prevention, and possible 
treatment, thereby decreasing negative sequelae of ICU delirium.  
Nevertheless, even when delirium or delirium risk is identified early, preventative methods 
or interventional management yields poor results. Haloperidol, the standard typical antipsychotic 
used for delirium, causes extrapyramidal adverse effects in patients and has recently been found 
to not be effective in decreasing delirium symptomology.30 Other atypical antipsychotics such as 
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risperidone, olanzapine, or quetiapine do not improve outcomes in patients who develop ICU 
delirium.14 Benzodiazepines have also not been helpful to control non-alcohol related delirium.12 
However, one study found that dexmedetomidine, a selective alpha-2 adrenergic receptor agonist, 
was associated with more delirium-free and coma- free days compared to lorazepam in 
mechanically ventilated ICU patients.12  Non-pharmacologic interventions for delirium address 
risk factors of delirium such as sleep deprivation and sensory impairment. One study focused on 
intervention protocols utilized for at-risk older adults, and compared the rate of occurrence and 
duration of delirium in older adults receiving usual care. These protocols covered a wide range of 
activities: orientation protocols included boards with dates and names; therapeutic activities 
protocol used cognitively stimulating activities three times a day with word games or discussion 
of current events; non-pharmacologic sleep protocol at bedtime utilized warm drinks and 
relaxation music; sleep enhancement protocol worked on noise reduction in the environment and 
readjusting schedules around sleeping; early mobilization protocol required participants to 
exercise three times a day and minimize immobilization equipment such as restraints and catheters; 
vision protocol reinforced participants to use glasses, magnifying glasses, and introduced more 
large-print books and telephone keypads; hearing protocol encouraged the usage of special 
communication techniques and amplifying devices; and the dehydration protocol encouraged oral 
intake of fluid.13 Incorporating this extensive environmental and treatment modification protocol 
did decrease the incidence of delirium (9.9% vs. 15%) and total number of days of delirium (105 
days vs. 161 days) in older adults. However, results were dependent on consistent utilization of 
the labor-intensive interventions which is challenging and often not feasible in non-research 
settings. The intervention was significantly less effective once delirium developed, reinforcing that 
the most important treatment of delirium is prevention.13 Applying these tactics in a hospital’s ICU 
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poses another set of obstacles due to physiologic or hemodynamic instability and limited time for 
providers to administer these tools. While behavioral interventions and environmental 
modification decreases delirium incidence somewhat, it remains a persistent problem.  
Identification of individuals at risk of delirium, and preventative or treatment strategies 
targeting pathology would improve delirium care and patient outcomes. To date, there is not a 
clear understanding of related pathology to provide efficient, focused interventional treatment. 
Furthermore, the biology driving ICU delirium symptoms is unknown, hampering advances in 
evidence-based care towards reducing the burden of delirium on ICU patients. There are countless 
widely accepted predisposing risk factors for ICU delirium, but many critical patients who do not 
develop delirium have these risk factors, limiting specificity. Risk factors include advanced age, 
hypertension, diabetes, previous psychiatric history, hypoxia, hypothermia, prolonged mechanical 
ventilation, and disrupted sleep patterns.11 Without a clearer mechanism to identify patients who 
are at a higher risk for developing delirium, patients are at risk to be under-diagnosed and 
insufficiently treated. 
Current research proposes ICU delirium is a consequence of sustained systemic 
inflammation.  Apolipoprotein E (APOE) genotype, a gene with functional polymorphisms, has 
been associated with neuro-inflammation and delirium in elderly medical inpatients both in and 
out of the ICU.15,33 There has been conflicting evidence for a role of APOE in delirium as others 
have found no association, and a recent meta-analysis found no relationship.16,34 Individuals who 
were admitted with a hip fracture were found to have an association between delirium and 
increased levels of C-reactive protein and soluble IL-6 receptor.24 Other work has supported an 
association between IL-6, a pro-inflammatory cytokine, and delirium in ICU patients. Alexander 
et al. measured daily serum levels of specific biomarkers in ICU patients experiencing delirium.16 
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They found that there is an association between higher serum levels of IL-6 in ICU patients with 
delirium.16 Pre-operative IL-6 levels were also found to be significantly increased in a post-
operative delirium population.17 With this confirmation in the relationship between IL-6 and 
delirium, it is important to pursue the source of variability of this important biomarker.  
Important factors to consider with delirium are the mechanisms of the underlying and 
ongoing pathology that brought the patient to the ICU in the first place. Having an infection or 
systemic inflammatory response syndrome (SIRS) where there is inflammation throughout the 
body may change the pathway of delirium than if it were occurring in a patient without an 
inflammatory pathology. Specific pro-inflammatory and anti-inflammatory biomarkers were 
studied in patients with and without delirium and with or without infection or SIRS. Researchers 
found that the pro-inflammatory cytokine IL-8 was significantly associated with delirium in 
inflamed patients while anti-inflammatory cytokine IL-10 was associated with delirium in patients 
without inflammation.25 
Studying the gene and its polymorphisms can lead researchers into understanding more of 
the relationship between IL-6 and delirium. In its promoter region, IL-6 has a common single 
nucleotide polymorphism (SNP) of C and G at position -174, or rs1800795. There are conflicting 
reports of IL-6 -174C/G genotype, and specifically presence of the C allele, having protective 
characteristics across multiple conditions. Poor health outcomes have been associated with a  
-174GG expression, such as lipid abnormalities and increased risk of intracranial hemorrhage, 
whereas the -174CC expression has shown a potential to have protective factors against systemic- 
onset juvenile chronic arthritis (S-JCA) and Eales’ disease (ED).18,19,20,26 Research suggests that 
the IL-6 -174C/G polymorphism expression correlates with serum IL-6 concentration and disease 
processes; however, this has not been studied in the context of delirium or critical care.  
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In active S-JCA, a pro-inflammatory condition, patients experience systemic adverse 
effects such as high fevers, lymphadenopathy, hepatosplenomegaly, myalgia, arthritis, and 
increased amounts of inflammatory biomarker C-reactive protein (CRP).19 In addition to CRP, 
researchers found in this population IL-6 -174CC homozygotes had a decreased presence of plasma 
IL-6 than GG homozygotes and GC heterozygotes.19 The variation in the presence of these 
inflammatory biomarkers in association with the polymorphism is significant in its influence of 
developing S-JCA although other genetic or environmental triggers likely contribute to the 
development of this disease process. Sen et al. found that elevated IL-6 serum concentrations were 
associated with the inflammatory stage of Eale’s disease (ED), or an idiopathic inflammatory 
vasoproliferative disease of the retina.26 Polymorphisms at the position of -174 on IL-6, 
specifically the -174GG genotype, were found to be functionally significant with increased IL-6 
serum concentrations in patients with ED. The -174CG genotype was higher in their control group 
and found to have a protective factor against ED, suggesting the C allele has a protective response 
and can mask the effects of the G allele in heterozygotes.26 Another study found the -174CC 
genotype increased serum IL-6 levels, increasing gastrointestinal involvement in systemic 
sclerosis.27 Although a discrepancy over protective genotypes exists, all of the disease processes 
linked with IL-6 -174C/G polymorphisms have inflammatory pathways and mechanisms involved. 
Given the literature showing ICU delirium is a pro-inflammatory state, it is important to further 
analyze genetic variability of IL-6 in the context of delirium and if the -174C/G polymorphism is 
a protective or predisposing factor. Based on its association with IL-6 protein variability, pro-
inflammatory diseases and other poor health outcomes, IL-6 -174C/G has the potential in playing 
an important role in the inflammatory pathway that results in delirium.  
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Delirium has been described as organ failure of the brain.4 Nonetheless, the biopathology 
driving delirium symptoms remain poorly understood.7 Given the high level of variability in 
delirium, and particularly ICU delirium development with few specific predictors, it is important 
to consider exploring genetic variability in the context of delirium. Analyzing biomarkers that may 
predispose patients to delirium would help expand our knowledge and inform future work aimed 
at personalized medicinal approaches to improve patient outcomes. By exploring genetic factors 
that place patients at higher risk for delirium, the consequences of delirium can be diminished or 
avoided.  
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2.0  PURPOSE OF STUDY 
The purpose of this study was to explore a potential relationship between delirium and IL-6 -174 
C/G polymorphism. The specific aims of this study were to 1. determine if a specific genetic 
polymorphism has a higher frequency in individuals who developed delirium, and 2. to determine 
if it is associated with more days of delirium experienced.   
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3.0  MATERIALS AND METHODS 
3.1 STUDY DESIGN 
This study has a prospective, observational design. It utilized targeted allelic discrimination to 
determine IL-6 -174C/G genotype. The use of de-identified samples and participant’s demographic 
data, collected for a parent study (PI- S. Alexander), was approved by the University of 
Pittsburgh’s Institutional Review Board (STUDY18100068).   
3.2 PARTICIPANTS 
Participants in this study were originally recruited for the parent study which focused on genetic 
variability in inflammatory biomarkers and delirium. These participants were specifically studied 
for associations between delirium presence, duration, and outcomes in ICU patients with protein-
based inflammatory markers (IL-6, IL-8, and IL-10), APOE protein, and related genetic variability.  
Participants were recruited from a 24 bed Medical ICU and a 22 bed Surgical-Trauma 
ICU. After informed consent was obtained from the patient or proxy, demographic data 
including sex, age, race, history of inflammation/sepsis/infectious process, current 
inflammation/sepsis/infection process, anti-inflammatory or infection medications, was extracted 
from the medical records. Research staff assessed for delirium every morning for the first 5-10 
days with the CAM-ICU.  Days of delirium, presence of an acute brain injury (ABI; delirium or 
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coma), days of an ABI, number of days free of delirium, and number of days free from ABI were 
collected.  
Inclusion criteria for participants included age ≥18 years old, admission to ICU and on 
mechanical ventilation for greater than 24 hours, and no known preadmission cognitive disorder. 
Adults were the main focus of the population since children have a different ICU delirium 
frequency and recovery, likely due to biological differences.  The aim was to recruit individuals 
at highest risk for ICU delirium, so ensuring ICU admission and mechanical ventilation for 
greater than 24 hours targets that population. Cognitive disorders may bias delirium assessment 
and interpretation of results. Patients with current or pre-existing neurologic diseases or deficits, 
including alcohol withdrawal, mild cognitive impairment, dementia, hypoxia/anoxia, previous 
stroke or head injury, were excluded. Additional exclusion criteria included not having a proxy 
available to provide consent or being unable to consent themselves, and having a positive 
toxicology screen in which drugs or withdrawal from drugs may confound delirium results.  
Participants were Caucasian or African American, ranging from 18-85 years of age. The 
study protocol changed during the data collection period such that the first 77 participants had 
delirium data collected up to 5 days while 58 had delirium data collected for 10 days.  
3.3 DELIRIUM ASSESSMENT 
Delirium assessment was performed daily (10 days) to ensure capture of the ICU delirium 
development. To determine an accurate presence of delirium in participants, the Richmond 
Agitation Sedation Scale (RASS) was performed daily as a precursor to the CAM-ICU to measure 
sedation levels. Subjects with RASS scores rating between -3 to +4 underwent delirium assessment 
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using the CAM-ICU, while the remaining patients (RASS -4 or -5) or those who were not sedated 
but unresponsive, were designated as being in a comatose state (whether disease or drug induced). 
Participants were rated as either normal (CAM-ICU negative), delirious (CAM-ICU positive and 
RASS -3 or higher) or comatose (RASS -4 or -5).  Those who were categorized as comatose or 
delirious were further grouped into an acute brain dysfunction positive group, since both are states 
of acute cognitive dysfunction in ICU patients.  
The CAM-ICU was selected due to its ease of use, brevity, established reliability and 
validity, and frequent use enabling comparisons across studies. Raters were trained and tested to 
determine interrater reliability for the RASS and CAM-ICU by separately assessing patients, 
blinded to each other’s results, and continued training until 90% agreement was reached.  
3.4 DNA EXTRACTION AND QUANTIFICATION 
DNA was extracted from blood samples taken from existing arterial or central venous catheters 
daily (day 1-10) throughout the study.  One 3mL sample and one 5mL sample was taken from each 
participant for the parent study. Samples were stored in a refrigerator in a research laboratory in 
the clinical site until transfer to the molecular genetics lab at the University of Pittsburgh’s School 
of Nursing adjacent to the clinical site. DNA was extracted using a simple salting out technique 
and stored at 4⁰C until analyzed in batch.32 
. 
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3.5 GENETIC DATA COLLECTION 
Allelic discrimination of the samples was conducted using an Applied Biosystems
 
™ 
QuantStudio™ 3 Real-Time PCR System. To prepare for data collection, a master mix was created 
in a separate reservoir that contained 12.5µl Taqman Universal PCR Master Mix No AmpErase, 
0.625µl 40X concentration assay of rs1800795, and 10µl sterile water. This master mix was 
pipetted into a MicroAmp Optical 96-Well Reaction Plate with 23µl in each well. Then, 2µl of 
extracted DNA was then introduced into the well and centrifuged at 1500rpm to ensure all 
materials amalgamated. Once all of the wells had the master mix and DNA, an optical adhesive 
film covered the tops of the well plate to enhance fluorescent light for the PCR system to read. 
Each allele had a specific fluorescent symbol: The C allele was VIC specific on the X- axis and 
the G allele was FAM specific on the Y-axis.  
Table 1. Master Mix Preparation 
Sterile water         10µl 
40X Concentration Assay (rs1800795)     0.625µl   
TaqMan Universal PCR Master Mix No AmpErase   12.5µl 
Extracted DNA        2µl 
 
   25µl per sample 
 
The cycling conditions of the QuantStudio™ 3 Real-Time PCR System from Applied 
Biosystems™ required 5 steps of Holding, PCR, and Post-read. The holding stage maintained 
95°C for 10 minutes. The plates then entered the PCR stage which includes steps 2-4. Step 2 held 
the plates at 95°C for 15 seconds, and moved onto step 3 where the plates were reduced to 58°C 
for 1 minute and 30 seconds. Step 4 cycled steps 2 and 3 again 50 times. The post-read stage held 
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the plates at 60°C for 30 seconds. In total, the allelic discrimination was completed in 135 minutes 
for each plate. Any results that were inconclusive were excluded from further analysis.  
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Table 2. Cycling Conditions 
    Temperature           Time              Number of cycles 
Stage 1  95°C            10 minutes   1 cycle 
 
Stage 2  95°C            15 seconds   1 cycle 
 
Stage 3  58°C            1.5 minutes   1 cycle 
  
Stage 4 Repeat Stage 2 and 3     50 cycles 
Stage 5 60°C    30 seconds  1 cycle  
 
 
Figure 1. PCR System Genotype Plot 
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3.6 STATISTICAL ANALYSIS 
SPSS Statistics Version 24.0 Software (IBM Corp., Armonk, New York) was used to run statistical 
analyses on the collected data. 
3.6.1 Preliminary data analysis 
Absolute frequency and percentage were reported for all categorical variables while measures of 
central tendency and dispersion were obtained for continuous variables.   
Differences in the dependent variable of the presence of delirium subjects with different 
genotype (independent variable) were analyzed with a Pearson Chi-Square test. Categorical 
demographic data was also analyzed by delirium to identify any potential covariates: age, sex, 
race, history of inflammatory disease, acute process of inflammatory disease, and use of anti-
inflammatory medications.  To further explore any relationship, logistic regression test was also 
completed on these variables.  
Demographic data grouped by genotypes was examined with chi-square and ANOVA tests, 
and then examined with t-tests for delirium positive days.  
3.6.2 Analysis of specific aims 
Specific Aim 1. Determine if a specific genetic polymorphism has a higher frequency in 
individuals who developed delirium. To address specific aim 1, frequencies and percentages of IL-
6 genotypes, Chi-Square tests, and t-tests were completed with the dependent variable of the 
presence of delirium. Genotype was also analyzed with other independent variables to assess for 
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the presence of confounding variables. A univariate logistic regression test was completed on the 
presence of delirium as well.  
Specific Aim 2. Determine if this polymorphism is associated with more days of delirium 
experienced. To address specific aim 2, delirium days within each different genotype group was 
analyzed utilizing a t-test. 
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4.0  RESULTS 
The sample was comprised of 134 patients with clinical data and samples. The average age of 
the sample was 52.5 years old who were predominantly female (n = 75), Caucasian (n = 121), 
and had the heterozygous genotype CG (n = 61). Although, genotype variation was similar 
between GG (n = 55) and CG (n = 61). Additional demographic data collected on the patients 
are included in table 3.  
Table 3. Sample Demographics 
 
Age (years)  
Mean (Standard Deviation) 52.46 (17.23) 
Range (Min, Max) 67 (18, 85) 
Sex   
Male 59 (44%) 
Female 75 (56%) 
Race  
Caucasian  121 (90.3%) 
Black/African American 13 (9.7%) 
Other 0 (0%) 
Genotype  
GG 55 (41%) 
CG 61 (45.5%) 
CC  18 (13.4%) 
History of 
inflammation/sepsis/infection 
 
No 109 (81.3%) 
Yes 25 (18.7%) 
Acute inflammation/sepsis/infection  
No 110 (82.1%) 
Yes 24 (17.9%) 
Anti-inflammatory/infection 
medications 
 
No 103 (76.9%) 
Yes 31 (23.1%) 
Delirium Presence   
No 64 (47.8%) 
Yes 70 (52.2%) 
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Delirium Days  
Mean (Standard Deviation) 2.83 (1.93) 
Median 2.00 
 
 
 
Figure 2. Delirium Duration 
 
 
Acute respiratory failure and acute respiratory distress were the most common admitting 
diagnoses. About 64 patients (47.8%) never experienced delirium throughout the study while 70 
patients (52.2%) experienced delirium positive at least one day in the study. For the delirium 
positive sample, the average days of delirium experienced was 2.83 days (standard deviation [SD] 
1.93), with a median of 2 days. Figure 2 shows the unequal, skewed distribution of delirium 
positive days that patients experienced. 
Patients were recruited from the University of Pittsburgh’s Medical Center Presbyterian’s 
Medical ICU and Surgical-Trauma ICU. The assessment tools are standardized between the two 
different units, and both utilized the RASS and CAM–ICU to diagnosis delirium. Neither unit 
provided consistent, standardized delirium preventative measures for the patients, so the usage of 
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lights, reorientation, and administration of antipsychotics/sedatives for patients can be ignored for 
the purpose of this study due to lack of fidelity.  
The sample was grouped together by their respective genotypes to further understand the 
demographic distribution as reported in table 4 utilizing chi-square tests and an ANOVA test for 
age. Differences in genotype presentation are especially important when considering the different 
races present within the sample and the implications of allele frequencies in different races. There 
was a significant association between genotype and race (p = 0.018) and genotype and anti-
inflammatory/infection medications (p = 0.018).  
Table 5 presents the t-test results of analyzing effects of genotype on the amount of 
delirium positive days. Genotype was grouped as either G-positive, encompassing groups GG and 
CG compared to CC, or C-positive which encompassed groups CG and CC compared to GG.  
 
Table 4. Demographic Data by Genotype 
 GG 
(n=55) 
CG 
(n=61) 
CC 
(n=18) 
     p-Value 
Age (years) 
Minimum 
Maximum 
Average (Standard 
Deviation) 
 
18 
79 
54.3 (16.5) 
 
18 
85 
52.0 (17.8)  
 
19 
82 
48.5 (17.7) 
0.455 
Sex    0.997 
Male 24 (40.7%) 27 (45.8%) 8 (13.6%)  
Female 31 (41.3%) 34 (45.3%) 10 (13.3%)  
Race    0.018 
Caucasian 45 (37.2%) 58 (47.9%) 18 (14.9%)  
Black/African 
American 
10 (76.9%) 3 (23.1%) 0 (0.0%)  
Other 0 (0%) 0 (0%) 0 (0%)  
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History of 
inflammatory, sepsis, 
or infectious process 
   0.339 
Yes 7 (28%) 14 (56%) 4 (16%)  
No 48 (44%) 47 (43.1%) 14 (12.8%)  
Acute inflammatory, 
sepsis, or infectious 
pathway 
   0.677 
Yes  8 (33.3%) 12 (50%) 4 (16.7%)  
No 47 (42.7%) 49 (44.5%) 14 (12.7%)  
Anti-inflammatory 
and infection 
medications 
   0.018 
Yes 
No 
6 (19.4%) 
49 (47.6%) 
20 (64.5%) 
41 (39.8%) 
5 (16.2%) 
13 (12.6%) 
 
Presence of delirium 
Yes 
No 
 
29 (41.4%) 
26 (40.6%) 
 
33 (47.1%) 
28 (43.8%) 
 
8 (11.4%) 
10 (15.6%) 
0.768 
 
 
Table 5. Genotype and Delirium Positive Days 
 t-value (p-value) Mean difference 
(95% CI) 
C-Positive -0.754 (0.453) -0.355 (-1.294, 0.584) 
G-Positive 0.508 (0.613) 0.371 (-1.086, 1.828) 
 
 
Delirium distribution among the sample the demographic data was analyzed utilizing 
univariate analyses as reported in table 6. Pearson Chi-Square tests were completed on categorical 
variables to assess any relationship with delirium as displayed in table 7. Sex and delirium did not 
have a significant relationship (p = 0.268), race did not have a significant relationship with delirium 
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(p = 0.903), and genotype did not have a significant relationship as well (p = 0.768). Age is known 
risk factor for developing delirium, but was not found to have a significant association in this 
sample’s presence of delirium (p = 0.565).  
Table 6. Demographic Data by Delirium 
 Delirium 
Negative 
(n=64) 
Delirium Positive 
 
(n=70) 
Total 
 
(N=134) 
p-Value 
Age (years) 
Minimum 
Maximum 
Average 
(Standard 
Deviation) 
 
19 
85 
51.6 (16.6) 
 
18 
82 
53.3 (17.8)  
 
 
0.565 
Sex    0.268 
Male 25 (42.4%) 34 (57.6%) 59 (100%)  
Female 39 (52%) 36 (48%) 75 (100%)  
Race    0.903 
Caucasian 58 (47.9%) 63 (52.1%) 121 (100%)  
Black/African 
American 
6 (46.1%) 7 (53.8%) 13 (100%)  
Other 0 (0%) 0 (0%) 0 (0%)  
Genotype    0.768 
GG 26 (47.3%) 29 (52.7%) 55 (100%)  
CG 28 (45.9%) 33 (54.1%) 61 (100%)  
CC 10 (55.6%) 8 (44.4%) 18 (100%)  
History of 
inflammation, 
sepsis, infectious 
process 
   0.426 
Yes 17 (42.5%) 23 (57.5%) 40 (100%)  
No 47 (50%) 47 (50%) 94 (100%)  
Acute 
inflammation, 
   0.227 
 23 
 
Genotype and delirium were further analyzed utilizing a logistic regression test to control 
for potential explanatory variables of age, sex, race, history of inflammation/sepsis/infection, acute 
inflammatory/sepsis/infectious process, and anti-inflammatory/infection medications. The 
Hosmer and Lemeshow Test showed that the data did not conflict (p = 0.283) with any assumptions 
made by the binary logistic regression model. Even with all variables controlled for, none of the 
clinical data showed significant association with delirium as shown in table 7.  
Table 7. Binary Logistic Regression Test 
 OR (95% CI) p-Value 
Age 0.987, 1.029 0.458 
Sex (Male) 0.774, 3.220 0.209 
Race (Caucasian) 0.327, 3.654 0.885 
Genotype  0.724 
GG 0.389, 3.727 0.747 
CG 0.506, 4.425 0.466 
History of 
inflammation, sepsis, 
infection 
0.291, 2.327 0.713 
Acute inflammatory, 
sepsis, infectious 
process 
0.416, 2.661 0.915 
Anti-inflammatory, 
infection med 
0.762, 5.187 0.160 
 
sepsis, infectious 
process 
Yes 15 (39.5%) 23 (60.5%) 38 (100%)  
No 49 (51%) 47 (49%) 96 (100%)  
Anti-
inflammatory, 
infection 
medications 
   0.925 
Yes 26 (47.3%) 29 (52.7%) 55 (100%)  
No 38 (48.1%) 41 (51.9%) 79 (100%)  
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5.0  DISCUSSION 
Increased levels of pro-inflammatory cytokine IL-6 have been found in ICU patients who develop 
delirium and those with worse outcomes.16 Further exploration of IL-6 and delirium’s relationship 
could help provide insight into understanding delirium’s mechanisms. A functional polymorphism 
in IL-6 leads to genotypic variability in the production and expression of IL-6 serum concentration. 
In pro-inflammatory diseases, IL-6 -174 C/G polymorphism has been found to be a key 
determinant. Specifically, the minor allele C has been shown to be protective against the 
inflammatory diseases generating lower IL-6 concentration, while the G allele has been associated 
with increased serum concentrations of IL-6 in participants with active inflammatory 
diseases.18.19,20,26 Therefore, pursuing a study of this specific polymorphism, IL-6 -174 C/G, was a 
logical step in the exploration of the source of individual and genetic variability in delirium.   
We did not find the IL-6 -174 C/G polymorphism significantly associated with delirium 
presentation in patients nor the amount of delirium positive days. We utilized the binary logistic 
regression in an attempt to control for other variables, but still found no relationship. Other work 
has found the CC genotype of the IL-6 -174 genotype is protective against pro-inflammatory 
diseases, so the binary logistic regression model utilized this genotype as the reference group. 
Nonetheless, discrepancies between which allele had protective factors exists.27 This discrepancy 
was taken into account when analyzing the data as separated into either a C positive or G positive 
group. If there is one allele that has more influence on the gene expression, then separating into 
these groups would have accounted for it. Genotype and race was found to have a statistically 
significant association, as well as genotype and anti-inflammatory/infection medications. 
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Ancestral background influences our genetic makeup and the allelic frequencies of this 
polymorphism are different between races so this significant association was to be expected.  
Genotype and use of anti-inflammatory or infection medications were also found to have a 
statistically significant relationship. While this may be statistically significant, it may not be 
clinically relevant or significant. If we were analyzing medications and genotype in a different 
aspect, such as response to medications based on genotype, this would have been a significant 
finding. However, this variable was included as a potential covariate in delirium presentation, 
and these medications were not statistically significant within a chi-square analysis. Even further, 
when controlled for in a binary logistic regression test, anti-inflammatory/infection medications 
and delirium did not have a significant association. This relationship may also be a consequence 
of the small sample size and inadvertently calculating artifact as significant.  
Demographic information on patients such as history of inflammation/sepsis/infectious 
process, acute inflammation/sepsis/infectious process, and anti-inflammatory/infection 
medications, were included in the analysis to evaluate as potential confounding variables. Since 
delirium’s mechanisms involve the inflammatory pathway, a patient with a known history of 
inflammatory diseases, such as sepsis or other infection, would be more susceptible to having 
increased inflammatory biomarkers and risk to develop delirium. Likewise, this would also be true 
for a patient with an acute inflammatory process during their ICU admission. Additionally, it was 
important to this study to control take into account for any medications the participant may have 
been taking that would suppress inflammatory pathways. Despite control for a number of these 
potentially influential demographic and clinical variables, we did not find statistical significance.  
There was an uneven distribution between the three different genotypes within the sample. The C 
allele is the minor allele globally at a frequency of 0.258, while the G allele has a frequency of 
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0.741. In addition, these allele frequencies differ among races: the European population has a C 
allele frequency of 0.460 and a G allele frequency of 0.539, the African population’s C allele has 
a frequency of 0.075 and the G allele 0.925.35 
In this study, the sample contained heavily uneven groups of Caucasian and Black/African 
American participants. To further investigate allele frequencies within the sample, the Hardy-
Weinberg formula was applied and shown to be in equilibrium. From this population, the 
Caucasian group had a C allele frequency of 0.388 and a G allele frequency of 0.611. The 
Black/African American group had a C allele frequency of 0.115 and a G allele frequency of 0.885. 
This genotype distribution shows that this study had an overall under-representation of the C allele 
in Caucasians and G allele in African-Americans, while there was an overrepresentation of the G 
allele in Caucasians and C allele in African-Americans. This may have biased our results; however, 
the small number of minorities makes this unlikely. 
While delirium is a pro-inflammatory state with increased serum IL-6 levels noted in ICU 
patients, it does not appear that the IL-6 -174C/G allele is driving the variable pathology. There 
are other factors that may influence IL-6 expression. Epigenetic mechanisms that can modify 
transcription can complicate gene expression. For example, higher methylation of the IL-6 gene or 
other genetic variability may contribute to the condition. Likewise, upstream regulators like NF-
kappa B play important roles in activation of IL-6.31 Genetic variability in other pro-inflammatory 
genes may contribute to the increased IL-6 expression as well and may be an informative line of 
future work.  
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5.1 LIMITATIONS 
Limitations of this study included the sample size, uneven distribution within the sample, and 
confounding variables. With a small sample and attempting to understand potential protective 
factors of the minor allele expression, it is difficult to obtain even sample sizes within each 
genotype group. Nonetheless, having an even number of genotypes within each group would be 
ideal to see the association between the differing polymorphisms and delirium. 
Similarly, it is difficult to control comorbidities and effects of the environment on patients 
that may affect delirium outcome and presentation. Objective screening tools for delirium also 
limit consistency and reliability between users who administer the CAM-ICU. Working with a 
critically-ill population also limits who can be included in studies due to inability to provide 
consent or unforeseen future complications.  
5.2 CONCLUSION 
This study was unable to discover a significant relationship between the IL-6 -174 C/G 
polymorphism and its impact on delirium and days of delirium presentation. Nonetheless, 
delirium’s pathophysiology is still widely unknown but is proposed to be a consequence of 
sustained systemic inflammation. With research showing evidence that varying levels of 
inflammatory markers and proteins are associated with delirium, future studies should continue to 
pursue this route. Future studies should include larger sample size, equal distribution of genotypes, 
control for comorbidities, and control for more potential confounding variables, to ensure validity 
and reliability. Clinical implications of this study point to the future utilization of genetic 
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biomarkers as a tool to assess a patient’s risk or likelihood of developing a disease. Continuing to 
assess biomarkers that influence the pathophysiology of delirium may be helpful for delirium 
prevention, detection, and effective personalized treatment in those who are high risk to improve 
patient outcomes.  
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